Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To develop analyte specific reagents for the diagnosis of dengue fever virus
Subscribe to our email newsletter
Calbiotech has received a Small Business Innovative Research (SBIR) Phase I contract by the US Army Medical Research and Material command. Under terms of the agreement, Calbiotech is expected to develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.
The company said that the technology developed under this research project will enable an affordable FDA-approved method for diagnosing Dengue fever in blood/sera. This will enable medical personnel to adequately diagnose and react to Dengue fever outbreaks.
The company added that the Phase I award will allow Calbiotech to compete for $730,000 in Phase II funding. A Phase II project would expand the work to develop ASRs for rift valley fever, sand fly fever-toscana, crimean-congo fever, central european tick-borne encephalitis and chikungunya viruses in blood/sera from clinically ill patients.